Century Therapeutics

IPSCNASDAQ
$2.27
0.062.71%
At Close: -
$2.30
0.031.32%
After Hours: 8:54 AM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$34.00
Lowest Price Target1
$5.00
Consensus Price Target1
$16.44

Century Therapeutics (NASDAQ:IPSC) Stock, Analyst Ratings, Price Targets, Predictions

Century Therapeutics Inc has a consensus price target of $16.44, established from looking at the 35 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co. on June 17, 2024, June 4, 2024, and May 10, 2024. With an average price target of $11.33 between Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 392.75% upside for Century Therapeutics Inc from these 3 analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
1
Apr
0
0
0
0
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
HC Wainwright & Co.
Canaccord Genuity
JP Morgan
EF Hutton

1calculated from analyst ratings

Analyst Ratings for Century Therapeutics

Buy NowGet Alert
06/17/2024Buy Now421.74%Piper Sandler
Edward Tenthoff
$9 → $12MaintainsOverweightGet Alert
06/04/2024Buy Now378.26%HC Wainwright & Co.
Mitchell Kapoor
$11 → $11ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now378.26%HC Wainwright & Co.
Mitchell Kapoor
$13 → $11MaintainsBuyGet Alert
04/12/2024Buy Now291.3%Piper Sandler
Edward Tenthoff
$10 → $9ReiteratesOverweight → OverweightGet Alert
03/15/2024Buy Now943.48%Canaccord Genuity
Bill Maughan
$22 → $24MaintainsBuyGet Alert
03/15/2024Buy Now465.22%HC Wainwright & Co.
Mitchell Kapoor
→ $13ReiteratesBuy → BuyGet Alert
12/07/2023Buy Now465.22%HC Wainwright & Co.
Mitchell Kapoor
→ $13ReiteratesBuy → BuyGet Alert
08/28/2023Buy Now117.39%JP Morgan
Eric Joseph
$28 → $5DowngradeOverweight → NeutralGet Alert
08/10/2023Buy Now334.78%Piper Sandler
Edward Tenthoff
$14 → $10MaintainsOverweightGet Alert
08/10/2023Buy Now465.22%HC Wainwright & Co.
Mitchell Kapoor
$17 → $13MaintainsBuyGet Alert
08/10/2023Buy Now595.65%EF Hutton
Tony Butler
→ $16ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now639.13%Chardan Capital
Geulah Livshits
$19 → $17MaintainsBuyGet Alert
05/12/2023Buy Now639.13%HC Wainwright & Co.
Mitchell Kapoor
→ $17ReiteratesBuy → BuyGet Alert
04/17/2023Buy Now595.65%EF Hutton
Tony Butler
→ $16MaintainsBuyGet Alert
04/13/2023Buy Now639.13%HC Wainwright & Co.
Mitchell Kapoor
→ $17Reiterates → BuyGet Alert
03/22/2023Buy Now726.09%Chardan Capital
Geulah Livshits
→ $19Reiterates → BuyGet Alert
03/17/2023Buy Now639.13%HC Wainwright & Co.
Mitchell Kapoor
$19 → $17MaintainsBuyGet Alert
03/16/2023Buy Now595.65%EF Hutton
Tony Butler
→ $16Reiterates → BuyGet Alert
02/09/2023Buy Now726.09%HC Wainwright & Co.
Mitchell Kapoor
→ $19Reiterates → BuyGet Alert
01/06/2023Buy Now595.65%EF Hutton
Tony Butler
$18 → $16MaintainsBuyGet Alert
01/06/2023Buy Now508.7%SVB Leerink
Daina Graybosch
$20 → $14MaintainsOutperformGet Alert
01/06/2023Buy Now508.7%Piper Sandler
Edward Tenthoff
$24 → $14MaintainsOverweightGet Alert
01/06/2023Buy Now726.09%HC Wainwright & Co.
Mitchell Kapoor
$25 → $19MaintainsBuyGet Alert
01/05/2023Buy Now682.61%EF Hutton
Tony Butler
→ $18Initiates → BuyGet Alert
12/27/2022Buy Now726.09%Chardan Capital
Geulah Livshits
→ $19Initiates → BuyGet Alert
11/14/2022Buy Now986.96%HC Wainwright & Co.
Mitchell Kapoor
$27 → $25MaintainsBuyGet Alert
10/31/2022Buy Now552.17%Guggenheim
Kelsey Goodwin
→ $15Initiates → BuyGet Alert
05/23/2022Buy Now1073.91%HC Wainwright & Co.
Mitchell Kapoor
→ $27Initiates → BuyGet Alert
05/17/2022Buy Now856.52%Piper Sandler
Edward Tenthoff
$38 → $22MaintainsOverweightGet Alert
04/29/2022Buy Now1073.91%SVB Leerink
Daina Graybosch
$32 → $27MaintainsOutperformGet Alert
11/19/2021Buy Now1291.3%SVB Leerink
Daina Graybosch
MaintainsOutperformGet Alert
07/13/2021Buy Now1378.26%B of A Securities
Geoff Meacham
Initiates → BuyGet Alert
07/13/2021Buy Now1334.78%SVB Leerink
Daina Graybosch
Initiates → OutperformGet Alert
07/13/2021Buy Now1639.13%JP Morgan
Eric Joseph
Initiates → OverweightGet Alert
07/13/2021Buy Now1552.17%Piper Sandler
Edward Tenthoff
Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Century Therapeutics (IPSC) stock?

A

The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Piper Sandler on June 17, 2024. The analyst firm set a price target for $12.00 expecting IPSC to rise to within 12 months (a possible 421.74% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Century Therapeutics (IPSC)?

A

The latest analyst rating for Century Therapeutics (NASDAQ:IPSC) was provided by Piper Sandler, and Century Therapeutics maintained their overweight rating.

Q

When was the last upgrade for Century Therapeutics (IPSC)?

A

There is no last upgrade for Century Therapeutics

Q

When was the last downgrade for Century Therapeutics (IPSC)?

A

The last downgrade for Century Therapeutics Inc happened on August 28, 2023 when JP Morgan changed their price target from $28 to $5 for Century Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Century Therapeutics (IPSC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Century Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Century Therapeutics was filed on June 17, 2024 so you should expect the next rating to be made available sometime around June 17, 2025.

Q

Is the Analyst Rating Century Therapeutics (IPSC) correct?

A

While ratings are subjective and will change, the latest Century Therapeutics (IPSC) rating was a maintained with a price target of $9.00 to $12.00. The current price Century Therapeutics (IPSC) is trading at is $2.30, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch